about
Efficacy and toxicity of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer.A feasibility study of weekly docetaxel with capecitabine in ovarian cancer: a promising combination of two active drugs with a potential for synergism.Targeting the mammalian target of rapamycin in myxoid chondrosarcoma.The yield of targeted genotyping for the recurring mutations in BRCA1/2 in Israel.Mutational analysis of candidate genes in Israeli male breast cancer cases.Cranial irradiation in childhood mimicking neurofibromatosis type II.Metastatic uterine leiomyosarcomas: a single-institution experienceThe protective effect of zoledronic acid on bone loss in postmenopausal women with early breast cancer treated with sequential tamoxifen and letrozole: a prospective, randomized, phase II trialCombined weekly carboplatin and paclitaxel as primary treatment of advanced epithelial ovarian carcinomaClinical activity of mTOR inhibition in combination with cyclophosphamide in the treatment of recurrent unresectable chondrosarcomasThe yield of full BRCA1/2 genotyping in Israeli high-risk breast/ovarian cancer patients who do not carry the predominant mutationsAccuracy of Risk Prediction Models for Breast Cancer and BRCA1/BRCA2 Mutation Carrier Probabilities in IsraelBreast cancer surveillance for BRCA1/2 mutation carriers - is "early detection" early enough?Circulating cell-free DNA (cfDNA) levels in BRCA1 and BRCA2 mutation carriers: A preliminary studyDiagnostic yield of multigene panel testing in an Israeli cohort: enrichment of low-penetrance variantsDe novo pathogenic germline variant in PALB2 in a patient with pancreatic cancerThe yield of full BRCA1/2 genotyping in Israeli Arab high-risk breast/ovarian cancer patientsThe spectrum of BRCA1 and BRCA2 pathogenic sequence variants in Middle Eastern, North African, and South European countriesMultigene panel testing in unselected Israeli breast cancer cases: mutational spectrum and use of BRCA1/2 mutation prediction algorithmsThe rate of the recurrent MSH6 mutations in Ashkenazi Jewish breast cancer patientsUterine cancer in Jewish Israeli BRCA1/2 mutation carriers
P50
Q33373957-BD0A6CEB-849F-4539-B657-6AE3EC775856Q45972087-B46C6518-D954-4430-A94E-038CBF6C66A8Q46338130-45441FE8-B2F6-4044-BA43-1C451989BC05Q47686082-2F0E2AF4-3850-4A1B-A6F1-D3F4B956FFEAQ51416641-5F0D0AD5-C8F4-45FD-BB06-16E6422EDF42Q52098198-31985B35-A243-465F-857B-2B8A7CE46AC6Q64043039-94371F71-51FF-4B84-A095-260BA4672C50Q82884961-A722391E-6BE3-4BFB-BDA5-50135B826553Q83840781-9EDF3A87-3ECE-41A8-9E66-E971FAC01DE8Q87423544-90C0853F-930B-4F48-91A7-126D51980145Q90264213-D8D155D8-4232-446E-8FD7-D04C72996DE5Q90644812-25282B2D-F76E-40B9-A4D7-EBC35CE04F7FQ91415410-61167DCF-84B4-4FC3-BB54-F8EF07CE31ACQ91838401-6B3DBF99-8477-46C3-ACDA-838ACBADB5F7Q92027222-9737D7AB-4978-4DF2-886D-7918E313B4EBQ92137036-FEF821D0-245F-4B09-B635-E56F193121FBQ92329607-530E2A39-4E45-4837-AAF4-F6F5CAE19840Q92832186-0261F24C-80CC-40B4-B8E7-BCEF56C3B34AQ93067018-3C7D50E1-9A7F-4FCA-A470-BB66F48A914EQ93380554-89F3A822-D0B1-422C-B547-2728DC1038A6Q93390874-D28ACD68-0D0E-438B-8149-9FDF5A68058D
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Rinat Bernstein
@en
Rinat Bernstein
@nl
type
label
Rinat Bernstein
@en
Rinat Bernstein
@nl
prefLabel
Rinat Bernstein
@en
Rinat Bernstein
@nl
P31
P496
0000-0002-4068-9514